Sandoz, a Novartis division, and Biocon have entered a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.
Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products, and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company’s strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America and the EU, while Biocon will lead commercialization in rest of the world.
“Today’s announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future,” said Richard Francis, chief executive officer of Sandoz. “Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics.”
Sandoz is a global leader in biosimilars, with five biosimilars currently marketed worldwide, as well as a leading global pipeline. Biocon has successfully developed and taken a range of novel biologics, biosimilar antibodies, rh-insulin and insulin analogs from ‘lab to market’.
